Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [68Ga]Ga-PSMA-11 PET/CT Study.
Kluge K, Einspieler H, Haberl D, Spielvogel C, Stoiber S, Vraka C, Papp L, Wunsch S, Egger G, Kramer G, Grubmüller B, Shariat S, Hacker M, Kenner L, Haug A. Kluge K, et al. Among authors: grubmuller b. J Nucl Med. 2024 Jan 2;65(1):63-70. doi: 10.2967/jnumed.123.266158. J Nucl Med. 2024. PMID: 38050125 Free PMC article.
Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI.
Papp L, Spielvogel CP, Grubmüller B, Grahovac M, Krajnc D, Ecsedi B, Sareshgi RAM, Mohamad D, Hamboeck M, Rausch I, Mitterhauser M, Wadsak W, Haug AR, Kenner L, Mazal P, Susani M, Hartenbach S, Baltzer P, Helbich TH, Kramer G, Shariat SF, Beyer T, Hartenbach M, Hacker M. Papp L, et al. Among authors: grubmuller b. Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1795-1805. doi: 10.1007/s00259-020-05140-y. Epub 2020 Dec 19. Eur J Nucl Med Mol Imaging. 2021. PMID: 33341915 Free PMC article. Clinical Trial.
Response to [ 177 Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases.
Zisser L, Yu J, Oszwald A, Wollenweber T, Kretschmer-Chott E, Grubmüller B, Kramer G, Shariat SF, Mitterhauser M, Vraka C, Hacker M, Haug AR, Rasul S. Zisser L, et al. Among authors: grubmuller b. Nucl Med Commun. 2022 Nov 1;43(11):1113-1120. doi: 10.1097/MNM.0000000000001611. Epub 2022 Sep 19. Nucl Med Commun. 2022. PMID: 36120814 Free PMC article.
Consecutive Prostate-Specific Membrane Antigen (PSMA) and Antigen Receptor (AR) PET Imaging Shows Positive Correlation with AR and PSMA Protein Expression in Primary Hormone-Naïve Prostate Cancer.
Al Jalali V, Wasinger G, Rasul S, Grubmüller B, Wulkersdorfer B, Balber T, Mitterhauser M, Simon J, Hacker M, Shariat S, Egger G, Zeitlinger M. Al Jalali V, et al. Among authors: grubmuller b. J Nucl Med. 2023 Jun;64(6):863-868. doi: 10.2967/jnumed.122.264981. Epub 2023 Jan 19. J Nucl Med. 2023. PMID: 36657982
68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making.
Grubmüller B, Baltzer P, D'Andrea D, Korn S, Haug AR, Hacker M, Grubmüller KH, Goldner GM, Wadsak W, Pfaff S, Babich J, Seitz C, Fajkovic H, Susani M, Mazal P, Kramer G, Shariat SF, Hartenbach M. Grubmüller B, et al. Among authors: grubmuller kh. Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):235-242. doi: 10.1007/s00259-017-3858-2. Epub 2017 Oct 26. Eur J Nucl Med Mol Imaging. 2018. PMID: 29075832 Free PMC article.
PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact.
Grubmüller B, Baltzer P, Hartenbach S, D'Andrea D, Helbich TH, Haug AR, Goldner GM, Wadsak W, Pfaff S, Mitterhauser M, Balber T, Berroteran-Infante N, Grahovac M, Babich J, Seitz C, Kramer G, Susani M, Mazal P, Kenner L, Shariat SF, Hacker M, Hartenbach M. Grubmüller B, et al. Clin Cancer Res. 2018 Dec 15;24(24):6300-6307. doi: 10.1158/1078-0432.CCR-18-0768. Epub 2018 Aug 23. Clin Cancer Res. 2018. PMID: 30139879
Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.
Grubmüller B, Senn D, Kramer G, Baltzer P, D'Andrea D, Grubmüller KH, Mitterhauser M, Eidherr H, Haug AR, Wadsak W, Pfaff S, Shariat SF, Hacker M, Hartenbach M. Grubmüller B, et al. Among authors: grubmuller kh. Eur J Nucl Med Mol Imaging. 2019 May;46(5):1063-1072. doi: 10.1007/s00259-018-4236-4. Epub 2018 Dec 19. Eur J Nucl Med Mol Imaging. 2019. PMID: 30569186 Free PMC article.
Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy.
Abufaraj M, Grubmüller B, Zeitlinger M, Kramer G, Seitz C, Haitel A, Baltzer P, Hacker M, Wadsak W, Pfaff S, Wiatr T, Mitterhauser M, Shariat SF, Hartenbach M. Abufaraj M, et al. Among authors: grubmuller b. Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2169-2177. doi: 10.1007/s00259-019-04361-0. Epub 2019 Jun 29. Eur J Nucl Med Mol Imaging. 2019. PMID: 31254037 Free PMC article. Clinical Trial.
Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer.
Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D'Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, Shariat SF, Hacker M, Kramer G, Hartenbach M. Grubmüller B, et al. Among authors: grubmuller kh. Prostate. 2020 Jan;80(1):74-82. doi: 10.1002/pros.23919. Epub 2019 Oct 15. Prostate. 2020. PMID: 31614001
41 results